# BMN 110 Phase 3B in Australian Patients

> **NCT01966029** · PHASE3 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 13 (actual)

## Conditions studied

- Mucopolysaccharidosis IVA (Morquio A Syndrome)

## Interventions

- **DRUG:** BMN 110

## Key facts

- **NCT ID:** NCT01966029
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966029, "BMN 110 Phase 3B in Australian Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01966029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*